shutterstock_1106804450_penpics_studio

PENpics Studio / Shutterstock.com

19 October 2021GenericsAlex Baldwin

Azurity sues Bionpharma over newly issued patent

Azurity Pharmaceuticals has sued Massachusetts drug company Bionpharma, claiming that its generic of Azurity’s Epaned product infringes on a brand new patent.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Apotex and Strides to merge Australia generics business

15 May 2018 Canadian generics maker Apotex and India-based Strides Shasun will merge their Australian operations in a bid to create the leading player in the Australian generics pharmaceutical market.

Eli Lilly targets more than 30 generics in Effient patent case

17 March 2014 Eli Lilly has filed suit against more than 30 generic drug makers at the US District Court for the Southern District of Indiana for allegedly infringing three patents related to platelet inhibitor drug Effient (prasugrel).

More on this story

Apotex and Strides to merge Australia generics business

15 May 2018 Canadian generics maker Apotex and India-based Strides Shasun will merge their Australian operations in a bid to create the leading player in the Australian generics pharmaceutical market.

Eli Lilly targets more than 30 generics in Effient patent case

17 March 2014 Eli Lilly has filed suit against more than 30 generic drug makers at the US District Court for the Southern District of Indiana for allegedly infringing three patents related to platelet inhibitor drug Effient (prasugrel).

More on this story

Apotex and Strides to merge Australia generics business

15 May 2018 Canadian generics maker Apotex and India-based Strides Shasun will merge their Australian operations in a bid to create the leading player in the Australian generics pharmaceutical market.

Eli Lilly targets more than 30 generics in Effient patent case

17 March 2014 Eli Lilly has filed suit against more than 30 generic drug makers at the US District Court for the Southern District of Indiana for allegedly infringing three patents related to platelet inhibitor drug Effient (prasugrel).

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York